Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No randomized, controlled trial of screening for diabetes has been conducted. In the absence of direct evidence, cost-effectiveness models may provide guidance about preferred screening strategies. OBJECTIVE: To estimate the incremental cost-effectiveness of 2 diabetes screening strategies: screening targeted to people with hypertension and universal screening. DESIGN: Markov model. DATA SOURCES: United Kingdom Prospective Diabetes Study, Hypertension Optimal Treatment trial, and recent cost data. TARGET POPULATION: General primary care population in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Health care system. INTERVENTIONS: Diabetes screening targeted to people with hypertension and universal screening. OUTCOME MEASURES: Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 U.S. dollars) and QALYs discounted at a 3% annual rate. RESULTS OF BASE-CASE ANALYSIS: At all ages, incremental cost-effectiveness ratios were more favorable for screening targeted to people with hypertension than for universal screening. For example, at age 55 years, the cost per QALY for targeted screening compared with no screening was 34,375 dollars, whereas the cost per QALY for universal screening compared with targeted screening was 360,966 dollars. Screening was more cost-effective for ages 55 to 75 years than for younger ages. RESULTS OF SENSITIVITY ANALYSIS: In single-way and probabilistic sensitivity analyses, findings were robust to therapy costs, screening costs, screening lead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk reduction for stroke attributable to intensive hypertension control. LIMITATIONS: We did not consider screening targeted to persons with dyslipidemia, and we used studies of people whose diabetes was detected clinically to estimate screening benefits. CONCLUSIONS: Diabetes screening targeted to people with hypertension is more cost-effective than universal screening. The most cost-effective strategy is targeted screening at age 55 to 75 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, screening targeted to individuals with hypertension reduces the QALY from $360,966 to $34,375, with ages between 55 and 75 years being the most cost-effective (33).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [33]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Although new research shows that intensive treatment can reduce the development of diabetes (34, 35), cost-effectiveness models examining this question will need to make assumptions about the effect of reductions in diabetes incidence on various diabetes complications.”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Although new research shows that intensive treatment can reduce the development of diabetes (34, 35), cost-effectiveness models examining this question will need to make assumptions about the effect of reductions in diabetes incidence on various diabetes complications.”
BackgroundTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 2×
“Treatment of hypertension is modeled as standard (with a target diastolic blood pressure of 90 mm Hg) or intensive (with a target diastolic blood pressure of 80 mm Hg), as in the HOT trial (14).”
BackgroundHarris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703 · cited 6×
“The prevalence of undiagnosed diabetes may have changed since the National Health and Nutrition Examination Survey III.”
BackgroundMethodInfluentialScreening for type 2 diabetes.
Engelgau, M. M., Narayan, K. M., & Herman, W. H. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1563 · Cited by 1,027
Self-citationProbabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach
Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. (1985) · Medical Decision Making · doi:10.1177/0272989x8500500205 · Cited by 860 · cited 1×
“We used the logistic normal distribution for most parameters (25) but used uniform and triangular distributions when appropriate (Appendix Tables 1 to 10, available at www.”
Method
Research works printed but not linked: 4
- Marshall KG, 1999, CMAJ, 160, 1592
- American Diabetes Association., 2001, Diabetes Care, 24, S21
- Estacio RO, 2000, Diabetes Care, 23, B54
- 10.1001/archinte.1992.00400150120022 · doi:10.1001/archinte.1992.00400150120022 · Paper page
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus
Muller, L. M. A. J., Gorter, K. J., Hak, E., Goudzwaard, W. L., Schellevis, F. G., Hoepelman, A. I. M., & Rutten, G. E. H. M. (2005) · Clinical Infectious Diseases · doi:10.1086/431587 · Cited by 1,023
“mated prevalence of undiagnosed DM2 in patients with hypertension is ∼5% [37].”
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
“In contrast, screening targeted to individuals with hypertension reduces the QALY from $360,966 to $34,375, with ages between 55 and 75 years being the most cost-effective (33).”
Young, B. A., Lin, E. H. B., Korff, M. V., Simon, G., Ciechanowski, P. S., Ludman, E. J., Everson‐Stewart, S., Kinder, L. S., Oliver, M. M., Boyko, E. J., et al. (2008) · PubMed · Cited by 686
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Metadata
- Authors
- Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2004-05-04
- Volume
- 140
- Issue
- 9
- Pages
- 689-699
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2007583174
- Semantic Scholar
- 01532d57dde4f4385d1c07acaf9a2cf9c15f719d
- Cited by
- 178
- References
- 51
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 11 · 2013: 8 · 2012: 11
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (290-97-0011, 200-97-0621)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, diabetes screening, cost-effectiveness, targeted screening, universal screening, hypertension, quality-adjusted life years, primary care, Markov model, stroke risk reduction
- MeSH terms
- Adult, Aged, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Hypertension, Male, Markov Chains, Mass Screening, Middle Aged, Sensitivity and Specificity, Disease Progression, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-140-9-200405040-00008
- The paper
- Hoerger, T. J., Harris, R., Hicks, K. A., Donahue, K., Sorensen, S., & Engelgau, M. (2004). Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-140-9-200405040-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.